glp-1 obesity drug news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care The GLP-1 Revolution Continues

Glucagon-like peptide 1 (GLP-1) receptor agonist: The gastrointestinal tract releases GLP-1, a major incretin, in response to glucose consumption

Some individuals carry genetic variants associated with higher or lower baseline GLP-1 receptor expression, which may affect medication efficacy and the likelihood of sustained weight loss

Clinical evidence for glp-1 receptor agonists in aAzheimers disease: A systematic review

In a study also published in The New England Journal of Medicine a few months later in June 2021, those taking 5mg lost about 7.8kg (about 17lbs), those with 10mg lost 10.3kg (about 22.7lbs), and those on 15mg lost 12.4kg (about 27lbs)

The availability of semaglutide in different formulations, such as injections and oral tablets, provides patients with options that cater to their preferences